Indian Immunologicals Limited (IIL), a top Indian vaccine maker, responded on December 27, 2025, to claims of fake batches of its rabies vaccine Abhayrab circulating in India. IIL strongly denied the Australian health advisory alert. The alert claimed counterfeit Abhayrab vaccine batches have been in use since November 1, 2023, and told Australian travelers to restart vaccination. IIL said the fake batch (Batch No. KA24014, made in March 2024, expires February 2027) was detected early January 2025 and removed from shelves immediately. IIL reported the issue to Indian regulators and police and called it an isolated incident. The company highlighted that it has made over 210 million doses since 2000, serving India and 40 countries with a 40% market share in India. It stressed all vaccine batches pass tests by the Central Drugs Laboratory before release. Sunil Tiwari, IIL’s Vice President and Head of Quality Management, said, “Supplies made through government institutions and authorized distributors remain safe and of standard quality.” The company also informed the Australian Technical Advisory Group that Abhayrab meets WHO Good Manufacturing Practices and pharmacopeial standards. The vaccine is used for both pre-exposure and post-exposure rabies prevention. Meanwhile, the US Centers for Disease Control and Prevention recently warned travelers of rabies risk in India and Haiti, advising to avoid contact with dogs, cats, and wild animals. Rabies is a deadly virus affecting the nervous system but can be prevented with quick medical care after exposure.